Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2026-09-17 16:55:22 ET · period of report 2026-09-15 · accession 0001193125-26-394456 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 16:55 | 2026-09-15 | TRVI | Heffernan Michael Thomas | Dir | M - OptEx | $3.19 | +39.5K | 27.4K | New | +$126.1K |
| DMT | 2026-09-17 16:55 | 2026-09-15 | TRVI | Heffernan Michael Thomas | Dir | S - Sale+OE | $15.09 | -39.5K | 6,351 | -86% | -$595.8K |
| DMT | 2026-09-17 16:55 | 2026-09-15 | TRVI | Heffernan Michael Thomas | Dir | M - OptEx | $0.00 | -39.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 18,421 | $3.04 | 24,772 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-15 | S | D | 18,321 | $15.09 | 6,451 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. (F1) This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. |
| 3 | Common | Common Stock | 2026-09-15 | S | D | 100 | $15.88 | 6,351 | D | — | — | (F1) This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. |
| 4 | Common | Common Stock | 2026-09-15 | M | A | 21,052 | $3.33 | 27,403 | D | — | — | |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 20,952 | $15.09 | 6,451 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. (F1) This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. |
| 6 | Common | Common Stock | 2026-09-15 | S | D | 100 | $15.88 | 6,351 | D | — | — | (F1) This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. |
| 7 | Derivative | Stock Option (right to buy) | 2026-09-15 | M | D | 18,421 | $0.00 | 0 | D | $3.04 · — to — | 18,421 Common Stock | (F3) These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. (F4) These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027. |
| 8 | Derivative | Stock Option (right to buy) | 2026-09-15 | M | D | 21,052 | $0.00 | 0 | D | $3.33 · — to — | 21,052 Common Stock | (F5) These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. (F6) These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027. |